In tumors, TIM-3 competes with nucleic acids in binding HMGB1, highly expressed in tumor-infiltrating DCs, and in reducing their transport to the endosomes, thereby mitigating the innate immune response to tumor-associated nucleic acid [115]. This evidence concerns the gene HAVCR2 and neoplasm.